Metabolic Disorders the Post-COVID Period
About a fifth of the world's population suffers from one or more chronic diseases, which exposes them to an increased risk of severe coronavirus infection COVID-19. At the same time, metabolic disorders are often detected, the presence of which plays an important role in the pathogenesis of COVID-19 and is accompanied by a more severe manifestation of the disease. The largest number of hospitalizations and deaths in the world associated with a new coronavirus infection falls on elderly and senile people. Age and concomitant diseases characteristic of the elderly, such as obesity, diabetes mellitus, arterial hypertension, pulmonary, cardiovascular, and renal insufficiency affect the progression and prognosis of COVID-19. Now, more than 2 years after the initial outbreak of SARS-CoV-2, there is strong evidence that people with metabolic diseases are not only more susceptible to severe COVID-19, but also have an increased risk of certain complications. Thus, primary prevention remains the best strategy to avoid post-COVID syndrome and associated metabolic disorders.
Panina J.N., Vishnevskij V.I., Melchinskaja E.N., Vishnevskij M.V. 2023. Metabolic Disorders in the Post-COVID Period. Challenges in Modern Medicine. 46 (1): 5–15 (in Russian). DOI: 10.52575/2687-0940-2023-46-1-5-15
While nobody left any comments to this publication.
You can be first.
Belocerkovckaya Yu.G., Romanovckix A.G., Cmirnov I.P., Cinopal`nikov A.I. 2021. Dolgij COVID-19 [Long COVID-19]. Consilium Medicum. 23 (3): 261–268. doi: 10.26442/20751753.2021.3.200805
Bondarev C.A., Achkacov E.E., Cmirnov V.V., Shishkin A.N., Xudyakova N.V., Ry`bka T.G. 2020. Vliyanie arterial`noj gipertenzii i drugix faktorov ricka na razvitie fibrillyacii predcerdij u cportcmenov [Hypertension and other risk factors of atrial fibrillation in athletes]. Arterial`naya gipertenziya. 26 (4): 362–370. doi: 10.18705/1607-419X-2020-26-4-362-370
Kogan E.A., Berezovckij Yu.C., Procenko D.D., Bagdacaryan T.R., Greczov E.M., Demura C.A., Demyashkin G.A., Kalinin D.V., Kukleva A.D., Kurilina E.V., Nekracova T.P., Paramonova N.B., Ponomarev A.B., Radencka-Lopovok C.G., Cemenova L.A., Terty`chny`j A.C. 2020. Patologicheckaya anatomiya infekcii, vy`zvannoj SARS-CoV-2 [Pathological Anatomy of Infection Caused by SARS-CoV-2]. Cudebnaya medicina. 6 (2): 8–30. doi: 10.19048/2411-8729-2020-6-2-8-30
Ojnotkinova O.Sh., Maclennikova O.M., Larina V.N., Rzhevckaya E.V., Cy`rov A.V., Dedov E.I., Kryukov E.V., Ecin E.V., Zhuravleva M.V., Voevoda M.I., Demidova T.Yu., Achkacov E.E., Cpacckij A.A., Shaxnovich P.G. 2020. Coglacovannaya e`kcpertnaya poziciya po diagnoctike i lecheniyu ful`minantnogo miokardita v ucloviyax pandemii COVID-19 [Expert consensus statement on the diagnosis and treatment of fulminant myocarditis in the context of the COVID-19 pandemic]. Akademiya mediciny` i cporta. 1 (2): 28–40. doi: 10.15829/2712-7567-2020-2-13
Orlov Yu.P., Govorova N.V., Korpacheva O.V., Afanac`ev V.V., Xilenko I.A. 2021. O vozmozhnocti icpol`zovaniya preparatov gruppy` cukcinatov v ucloviyax gipokcii pri COVID-19 [On the Possibility of Using Succinate in Hypoxia Developing in COVID-19]. Obshhaya reanimatologiya. 17 (3): 78–98. doi: 10.15360/1813-9779-2021-3-78-98
Ucacheva E.V. 2016. Mify` i real`noct` kardioprotektivnoj terapii [Myths and reality of cardioprotective therapy]. 24 (9): 546–550.
Acuti Martellucci C., Flacco M.E., Cappadona R., Bravi F., Mantovani L., Manzoli L. 2020. SARS-CoV-2 pandemic: An. overview. Adv. Biol. Regul. 77: 100736. doi: 10.1016/j.jbior.2020.100736
Adhikari S.P., Meng S., Wu Y.J., Mao Y.P., Ye R.X., Wang Q.Z., Sun C., Sylvia S., Rozelle S., Raat H., Zhou H. 2020. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect. Dis. Poverty. 9 (1): 29. doi: 10.1186/s40249-020-00646-x
Alfano G., Fontana F., Mori G., Giaroni F., Ferrari A., Giovanella S., Ligabue G., Ascione E., Cazzato S., Ballestri M., Di Gaetano M., Meschiari M., Menozzi M., Milic J., Andrea B., Franceschini E., Cuomo G., Magistroni R., Mussini C., Cappelli G., Guaraldi G. 2022. Modena COVID-19 Working Group (MoCo19). Acid base disorders in patients with COVID-19. Int. Urol. Nephrol. 54 (2): 405–410. doi: 10.1007/s11255-021-02855-1
Avanzato V.A., Matson M.J., Seifert S.N., Pryce R., Williamson B.N., Anzick S.L., Barbian K., Judson S.D., Fischer E.R., Martens C., Bowden T.A., de Wit E., Riedo F.X., Munster V.J. 2020. Case study: Prolonged infectious SARSCoV-2 shedding from an asymptomatic immunocompromised cancer patient. Cell. 183 (7): 1901–1912. doi: 10.1016/j.cell.2020.10.049
Bezuidenhout M.C., Wiese O.J., Moodley D., Maasdorp E., Davids M.R., Koegelenberg C.F., Lalla U., Khine-Wamono A.A., Zemlin A.E., Allwood B.W. 2021. Correlating arterial blood gas, acid-base and blood pressure abnormalities with outcomes in COVID-19 intensive care patients. Ann. Clin. Biochem. 58 (2): 95–101. doi: 10.1177/0004563220972539
Cariou B., Pichelin M., Goronflot T., Gonfroy C., Marre M., Raffaitin-Cardin C., Thivolet C., Wargny M., Hadjadj S., Gourdy P. 2021. CORONADO investigators. Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO study. Diabetes Res. Clin. Pract.175. doi: 10.1016/j.diabres.2021.108695
Carrasco-Sánchez F.J., López-Carmona M.D., Martínez-Marcos F.J., Pérez-Belmonte L.M., Hidalgo-Jiménez A., Buonaiuto V., Suárez Fernández C., Freire Castro S.J., Luordo D., Pesqueira Fontan P.M., Blázquez Encinar J.C., Magallanes Gamboa J.O., de la Peña Fernández A., Torres Peña J.D., Fernández Solà J., Napal Lecumberri J.J., Amorós Martínez F., Guisado Espartero M.E., Jorge Ripper C., Gómez Méndez R., Vicente López N., Román Bernal B., Rojano Rivero M.G., Ramos Rincón J.M., Gómez Huelgas R. 2021. SEMI-COVID-19 Network. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry. Ann. Med. 53 (1): 103–116. doi: 10.1080/07853890.2020.1836566
Castañeda S., Remuzgo-Martínez S., López-Mejías R., Genre F., Calvo-Alén J., Llorente I., Aurrecoechea E., Ortiz A.M., Triguero A., Blanco R., Llorca J., González-Gay M.A. 2019. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol. 37: 465–473.
De Leo S., Lee S.Y., Braverman L.E. Hyperthyroidism. Lancet 2016; 388: 906–918. doi: 10.1016/S0140-6736(16)00278-6
Group R.C. 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 397: 1637–1645. doi: 10.1016/S0140-6736(21)00676-0
Guerstein S., Romeo-Aznar V., Dekel M., Miron O., Davidovitch N., Puzis R., Pilosof S. 2021. The interplay between vaccination and social distancing strategies affects COVID19 population-level outcomes. PLoS Comput Biol. 17 (8): e1009319. doi: 10.1371/journal.pcbi.1009319
Inaba H., Aizawa T. 2021. Coronavirus Disease 2019 and the Thyroid – Progress and Perspectives. Front Endocrinol (Lausanne). 12: 708333. doi: 10.3389/fendo.2021.708333
Kosiborod M.N., Esterline R., Furtado R.H.M., Oscarsson J., Gasparyan S.B., Koch G.G., Martinez F., Mukhtar O., Verma S., Chopra V., Buenconsejo J., Langkilde A.M., Ambery P., Tang F., Gosch K., Windsor S.L., Akin E.E., Soares R.V.P., Moia D.D.F., Aboudara M., Hoffmann Filho C.R., Feitosa A.D.M., Fonseca A., Garla V., Gordon R.A., Javaheri A., Jaeger C.P., Leaes P.E., Nassif M., Pursley M., Silveira F.S., Barroso W.K.S., Lazcano Soto J.R., Nigro Maia L., Berwanger O. 2021. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 9: 586–594. doi: 10.1016/S2213-8587(21)00180-7
Kudose S., Batal I., Santoriello D., Xu K., Barasch J., Peleg Y., Canetta P., Ratner L.E., Marasa M., Gharavi A.G., Stokes M.B., Markowitz G.S, D'Agati V.D. 2020. Kidney biopsy findings in patients with COVID-19. Journal of the American Society of Nephrology. 9 (31): 1959–1968. doi: 10.1681/ASN.2020060802
Mallah S.I., Ghorab O.K., Al-Salm S., Abdellatif O.S., Tharmaratnam T., Iskandar M A., Sefen, J.A.N., Sidhu P., Atallah B., El-Lababid, R., Al-Qahtan M. 2021. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 201: 35. doi: 10.1186/s12941-021-00438-7
Marfella R., Paolisso P., Sardu C., Bergamaschi L., D'Angelo E.C., Barbieri M., Rizzo M.R., Messina V., Maggi P., Coppola N., Pizzi C., Biffi M., Viale P., Galié N., Paolisso G. 2020. Negative impact of hyperglycaemia on tocilizumab therapy in COVID-19 patients. Diabetes Metab. 46: 403–405. doi: 10.1016/j.diabet.2020.05.005
Mazori A.Y., Bass I.R., Chan L., Mathews K.S., Altman D.R., Saha A., Soh H., Wen H.H., Bose S., Leven E., Wang J.G., Mosoyan G., Pattharanitima P., Greco G., Gallagher E.J. 2021. Hyperglycemia is associated with increased mortality in critically ill patients with COVID-19. Endocr Pract. 27 (2): 95–100. doi: 10.1016/j.eprac.2020.12.015
Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O'Hara M., Suett J., Dahmash D., Bugaeva P., Rigby I., Munblit D., Harriss E., Burls A., Foote C., Scott J., Carson G., Olliaro P., Sigfrid L., Stavropoulou C. 2021. Characterising long COVID: a living systematic review. BMJ Global Health. 6: e005427. doi: 10.1136/bmjgh-2021-005427
National Center for Biotechnology Information. 2022. PubChem Compound Summary for CID 10917, Levocarnitine. 2022; from https://pubchem.ncbi.nlm.nih.gov/compound/Levocarnitine.
Noh Y., Oh I.S., Jeong H.E., Filion K.B., Yu O.H.Y., Shin J.Y. 2021. Association between DPP-4 inhibitors and COVID-19-related outcomes among patients with type 2 diabetes. Diabetes Care. 44: e64–e66. doi: 10.2337/dc20-1824
Post-COVID Conditions. CDC, 2021, Updated July 12. 2021. [https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html].
Raman B., Bluemke D.A., Lüscher T.F., Neubauer S. 2022. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 43: 1157–1172. doi: 10.1093/eurheartj/ehac031
Santos A., Magro D.O, Evangelista-Poderoso R., Saad M.J.A. 2021. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr.13: 23. doi: 10.1186/s13098-021-00639-2
Scappaticcio L., Pitoia F., Esposito K., Piccardo A., Trimboli P. 2021. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord. 22 (4): 803-815. doi: 10.1007/s11154-020-09615-z
Seeherman S., Suzuki Y.J. 2021. Viral Infection and Cardiovascular Disease: Implications for the Molecular Basis of COVID-19 Pathogenesis. Int. J. Mol. Sci. 22 (4): 1659. doi: 10.3390/ijms22041659
Solerte S.B., D'Addio F., Trevisan R., Lovati E., Rossi A., Pastore I., Dell'Acqua M., Ippolito E., Scaranna C., Bellante R., Galliani S., Dodesini A.R., Lepore G., Geni F., Fiorina R.M., Catena E., Corsico A., Colombo R., Mirani M., De Riva C., Oleandri S.E., Abdi R., Bonventre J.V., Rusconi S., Folli F., Di Sabatino A., Zuccotti G., Galli M., Fiorina P. 2020. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care. 43: 2999–3006. doi: 10.2337/dc20-1521
Velavan T.P., Kieu Linh L.T., Kreidenweiss A., Gabor J., Krishna S., Kremsner P.G. 2021. Longitudinal monitoring of lactate in hospitalized and ambulatory COVID-19 patients. Am. J. Trop. Med. Hyg. 104 (3): 1041–1044. doi: 10.4269/ajtmh.20-1282
Zhou H., Yang J., Zhou C., Chen B., Fang H., Chen S., Zhang X., Wang L., Zhang L. 2021. A Review of SARS-CoV2: compared With SARS-CoV and MERS-CoV. Front Med (Lausanne). 8:628370. doi: 10.3389/fmed.2021.628370